MT Newswires
Viatris, Opus Genetics Say US FDA Agrees to Review New Drug Application for Potential Eye Condition Treatment
âž–
AI Sentiment
Neutral
5/10
- Home
- VTRS
VTRS
Viatris Inc.
as of 02-26-2026 9:38am EST
$16.35
+$0.27
+1.68%
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
| Founded: | 1961 | Country: | United States |
| Employees: | N/A | City: | CANONSBURG |
| Market Cap: | 14.8B | IPO Year: | 2019 |
| Target Price: | $11.83 | AVG Volume (30 days): | 9.2M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | -2.70 | EPS Growth: | -1160.00 |
| 52 Week Low/High: | $6.85 - $16.47 | Next Earning Date: | 05-27-2026 |
| Revenue: | $14,739,300,000 | Revenue Growth: | -4.46% |
| Revenue Growth (this year): | -2.25% | Revenue Growth (next year): | 1.60% |
| P/E Ratio: | -5.96 | Index: | |
| Free Cash Flow: | 2.0B | FCF Growth: | -18.53% |
Latest Viatris Inc. News
VTRS Breaking Stock News: Dive into VTRS Ticker-Specific Updates for Smart Investing
PR Newswire
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
📈
AI Sentiment
Highly Positive
8/10
StockStory
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Will UBS Upgrade And Inpefa’s First Global Launch Change Viatris' (VTRS) Narrative?
📊
AI Sentiment
Positive
7/10
Zacks
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics
âž–
AI Sentiment
Neutral
4/10
Compare VTRS vs Leading Stocks
See how VTRS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VTRS Viatris Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.